Emerging role of immune checkpoint blockade in pancreatic cancer

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

A. Bulumulle (Creator)

S. Laks (Creator)

S. Macherla (Creator)

Mahvish Muzaffar (Creator)

Abdul R. Naqash (Creator)

E. Zervos (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers , especially non-small cell lung cancer , melanoma , urothelial , and renal cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on available data , it's obvious that ICB has limited success in PDACs , which can be explained by the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. In this review article , we focus on PD-L1 expression and microsatellite instability (MSI) in PDAC , and their roles as prognostic and predictive markers. We also discuss data supporting combination therapies to augment cancer immunity cycle. Combining anti-PD-1/PD-L1 agents with other modalities such as vaccines , chemotherapy , and radiation could potentially overcome resistance patterns and increase immune responsiveness in PDAC.

Additional Information

Publication

Other

Macherla , S. , Laks , S. , Naqash , A. R. , Bulumulle , A. , Zervos , E. , & Muzaffar , M. (2018). Emerging role of immune checkpoint blockade in pancreatic cancer. International Journal of Molecular Sciences , 19(11) doi:10.3390/ijms19113505

Language: English

Date: 2018

Keywords

microsatellite instability, pancreatic adenocarcinoma, programmed death ligand

Subjects

Email this document to